Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wallemacq

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Revue Medicale De Liege|November 25, 2017
[Evolocumab (Repatha®) : a human monoclonal antibody against PCSK9 protein as potent cholesterol-lowering therapy]C Wallemacq
Revue Medicale De Liege|June 5, 2020
[A decade of progress in the management of dyslipidemia]C Wallemacq, N Paquot
Revue Medicale De Liege|April 9, 2020
[Ezetimibe-rosuvastatin fixed-dose combination (Myrosor®)]C Wallemacq, A J Scheen
Revue Medicale De Liege|December 9, 2022
[Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy]A J Scheen, C Wallemacq, P Lancellotti
Revue Medicale De Liege|February 10, 2022
[Bempedoïc acid, new cholesterol-lowering drug]A J Scheen, N Paquot, C Wallemacq
Revue Medicale De Liege|July 23, 2005
[The cost of type 2 diabetes: summary of the Cost of Diabetes in Europe-Type II study (CODE-2) and analysis of the situation in Belgium]C Wallemacq, L F Van Gaal, A J Scheen
Revue Medicale De Liege|March 22, 2019
[Management of hypertriglyceridaemia]A J Scheen, C Wallemacq, J De Flines, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Revue Medicale De Liege|November 25, 2017
[Evolocumab (Repatha®) : a human monoclonal antibody against PCSK9 protein as potent cholesterol-lowering therapy]C Wallemacq
Revue Medicale De Liege|June 5, 2020
[A decade of progress in the management of dyslipidemia]C Wallemacq, N Paquot
Revue Medicale De Liege|April 9, 2020
[Ezetimibe-rosuvastatin fixed-dose combination (Myrosor®)]C Wallemacq, A J Scheen
Revue Medicale De Liege|December 9, 2022
[Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy]A J Scheen, C Wallemacq, P Lancellotti
Revue Medicale De Liege|February 10, 2022
[Bempedoïc acid, new cholesterol-lowering drug]A J Scheen, N Paquot, C Wallemacq
Revue Medicale De Liege|July 23, 2005
[The cost of type 2 diabetes: summary of the Cost of Diabetes in Europe-Type II study (CODE-2) and analysis of the situation in Belgium]C Wallemacq, L F Van Gaal, A J Scheen
Revue Medicale De Liege|March 22, 2019
[Management of hypertriglyceridaemia]A J Scheen, C Wallemacq, J De Flines, et al.
Pageof 1